|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al: A randomized trial of chemoradiotherapy and
chemotherapy after resection of pancreatic cancer. N Engl J Med.
350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Neoptolemos JP, Stocken DD, Smith C Tudur,
Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D and
Büchler MW: Adjuvant 5-fluorouracil and folinic acid vs observation
for pancreatic cancer: Composite data from the ESPAC-1 and −3(v1)
trials. Br J Cancer. 100:246–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Neoptolemos JP, Stocken DD, Bassi C,
Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger
S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus
folinic acid vs gemcitabine following pancreatic cancer resection:
A randomized controlled trial. JAMA. 304:1073–1081. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maeda A, Boku N, Fukutomi A, Kondo S,
Kinoshita T, Nagino M and Uesaka K: Randomized phase III trial of
adjuvant chemotherapy with gemcitabine versus S-1 in patients with
resected pancreatic cancer: Japan Adjuvant Study Group of
Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol. 38:227–229. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB and Danenberg PV: Colorectal tumors responding to
5-fluorouracil have low gene expression levels of dihydropyrimidine
dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Clin Cancer Res. 6:1322–1327. 2000.PubMed/NCBI
|
|
10
|
Saif MW, Hashmi S, Bell D and Diasio RB:
Prognostication of pancreatic adenocarcinoma by expression of
thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and
its correlation with survival. Expert Opin Drug Saf. 8:507–514.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kondo N, Murakami Y, Uemura K, Sudo T,
Hashimoto Y, Nakashima A, Ohge H and Sueda T: Prognostic impact of
dihydropyrimidine dehydrogenase expression on pancreatic
adenocarcinoma patients treated with S-1-based adjuvant
chemotherapy after surgical resection. J Surg Oncol. 104:146–154.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakamura A, Hayashi K, Nakajima G,
Kamikozuru H, Okuyama R, Kuramochi H, Hatori T and Yamamoto M:
Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase
on the outcomes of patients treated with gemcitabine or S-1 as
adjuvant chemotherapy for advanced pancreatic cancer. Exp Ther Med.
2:1097–1103. 2011.PubMed/NCBI
|
|
13
|
Shimoda M, Kubota K, Shimizu T and Katoh
M: Randomized clinical trial of adjuvant chemotherapy with S-1
versus gemcitabine after pancreatic cancer resection. Br J Surg.
102:746–754. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scoazec JY and Sabourin JC: 2010: The
seventh edition of the TNM classification. Ann Pathol. 30:2–6.
2010.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aoyama T, Murakawa M, Katayama Y, Yamaoku
K, Kanazawa A, Higuchi A, Shiozawa M, Morimoto M, Yoshikawa T,
Yamamoto N, et al: Impact of postoperative complications on
survival and recurrence in pancreatic cancer. Anticancer Res.
35:2401–2409. 2015.PubMed/NCBI
|
|
16
|
Kondo N, Murakami Y, Uemura K, Sudo T,
Hashimoto Y, Nakashima A and Sueda T: Combined analysis of
dihydropyrimidine dehydrogenase and human equilibrative nucleoside
transporter 1 expression predicts survival of pancreatic carcinoma
patients treated with adjuvant gemcitabine plus S-1 chemotherapy
after surgical resection. Ann Surg Oncol. 19 Suppl 3:S646–S655.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakahara O, Takamori H, Tanaka H, Sakamoto
Y, Ikuta Y, Furuhashi S, Watanabe M, Beppu T, Hirota M, Kanemitsu K
and Baba H: Clinical significance of dihydropyrimidine
dehydrogenase and thymidylate synthase expression in patients with
pancreatic cancer. Int J Clin Oncol. 15:39–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang WB, Yang Y, Zhao YP, Zhang TP, Liao Q
and Shu H: Recent studies of 5-fluorouracil resistance in
pancreatic cancer. World J Gastroenterol. 20:15682–15690. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sasako M, Terashima M, Ichikawa W, Ochiai
A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T and Imamura
H: Impact of the expression of thymidylate synthase and
dihydropyrimidine dehydrogenase genes on survival in stage II/III
gastric cancer. Gastric Cancer. 18:538–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ichikawa W, Takahashi T, Suto K, Yamashita
T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y and Hirayama R:
Thymidylate synthase predictive power is overcome by irinotecan
combination therapy with S-1 for gastric cancer. Br J Cancer.
91:1245–1250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuramochi H, Hayashi K, Uchida K, Nakajima
G, Hatori T, Danenberg KD, Danenberg PV and Yamamoto M: High
intratumoral dihydropyrimidine dehydrogenase mRNA levels in
pancreatic cancer associated with a high rate of response to S-1.
Cancer Chemother Pharmacol. 63:85–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takechi T, Fujioka A, Matsushima E and
Fukushima M: Enhancement of the antitumour activity of
5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase
activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human
tumour cells. Eur J Cancer. 38:1271–1277. 2002. View Article : Google Scholar : PubMed/NCBI
|
